Medivation Inc.

Clinical research is centered on high-risk nonmetastatic prostate cancer, with attention to disease progression after definitive therapy and the use of hormonal and androgen-targeted treatment strategies.

• Androgen receptor inhibition
• Hormonal therapy
• Nonmetastatic prostate cancer
• Post-definitive therapy disease control

The sponsor’s research interest in this area includes evaluation of treatment approaches involving enzalutamide and leuprolide for men with aggressive localized disease patterns.